7 completed, 2 terminated, 1 not yet recruiting, 1 withdrawn. 11 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 11 | Completed 7, Terminated 2, Not yet recruiting 1, Withdrawn 1 |
Follow Pyelonephritis: new trials by email Literature Review of Pyelonephritis trials Research Report on Pyelonephritis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Fosfomycin Trometamol Compared With an Alternative Active Antibiotic as Step-down Therapy for the Treatment of Acute Pyelonephritis Due to Escherichia Coli in Elderly Women : a Randomized, Multicenter, Non-inferiority Trial Fosfomycin-trometamol (FT), Alternative antibiotic treatment - Escherichia Coli Infection, Elderly Women | Phase 3 | Not yet recruiting | Assistance Publique - Hôpitaux de Paris | 312 | 2026-12-01 | 2026-11-10 |
| Study of Ceftolozane/Tazobactam (MK-7625A) in Japanese Participants With Uncomplicated Pyelonephritis and Complicated Urinary Tract Infection (MK-7625A-014) MK-7625A 1.5 g (ceftolozane 1 g/tazobactam 0.5 g) - Urinary Tract Infection (UTI), Complicated Urinary Tract Infection | Phase 3 | Completed | Merck Sharp & Dohme LLC | 115 | 2016-04-14 | 2019-02-05 |
| CSE-1034 (Ceftriaxone+ Sulbactam+ EDTA) Compared to Meropenem in Complicated Urinary Tract Infections (cUTIs) Caused by ESBL Producing Gram Negative Bacteria CSE-1034 (Ceftriaxone + Sulbactam + EDTA), Meropenem - Urinary Tract Infection Complicated, Acute Pyelonephritis | Phase 3 | Completed | Venus Remedies Limited | 230 | 2014-01-11 | 2019-08-29 |
| Study Comparing the Safety and Efficacy of Intravenous CXA-201 and Intravenous Levofloxacin in Complicated Urinary Tract Infection, Including Pyelonephritis CXA-201, Levofloxacin - Complicated Urinary Tract Infection, Pyelonephritis | Phase 3 | Completed | Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 558 | 2011-06-20 | 2018-10-25 |
| A Safety and Tolerability Study of Doripenem Compared With Cefepime in Children Hospitalized With Complicated Urinary Tract Infections Doripenem, Doripenem placebo, Cefepime - Complicated Urinary Tract Infections or Pyelonephritis | Phase 3 | Terminated | Janssen Research & Development, LLC | 41 | 2010-12-01 | 2014-07-15 |
| Antibiotic Prophylaxis in Children With Pyelonephritis Trimethoprim Sulfamethoxazole, placebo - Pyelonephritis | Phase 3 | Withdrawn | University of Alberta | 2009-02-01 | 2015-01-16 | |
| Short-term Antibiotic Therapy for Pyelonephritis in Childhood ceftibuten - Pyelonephritis | Phase 3 | Terminated | IRCCS Burlo Garofolo | 36 | 2006-07-01 | 2012-02-17 |
| A Comparison of the Effectiveness and Safety of Levofloxacin to That of Ciprofloxacin in Treating Complicated Urinary Tract Infection and Acute Pyelonephritis. levofloxacin - Urinary Tract Infections, Pyelonephritis | Phase 3 | Completed | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 1109 | 2004-10-01 | 2011-06-10 |
| Doripenem in the Treatment of Complicated Lower Urinary Tract Infection or Pyelonephritis doripenem - Urinary Tract Infections, Pyelonephritis | Phase 3 | Completed | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 403 | 2004-03-01 | 2011-06-10 |
| Doripenem in the Treatment of Complicated Lower Urinary Tract Infection or Pyelonephritis doripenum - Urinary Tract Infections, Pyelonephritis | Phase 3 | Completed | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 741 | 2003-12-01 | 2011-06-10 |
| A Study of the Safety and Effectiveness of Oral Levofloxacin Compared With Oral Ciprofloxacin in the Treatment of Complicated Urinary Tract Infections Levofloxacin - Urinary Tract Infections, Bacteriuria | Phase 3 | Completed | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 578 | 1993-06-01 | 2011-05-23 |
Urinary Tract Infections (7) · Bacterial Infections (3) · Bacteriuria (1) · Cystitis (1) · Escherichia coli Infections (1) · Infections (1) · Urinary Bladder, Neurogenic (1) · Urologic Diseases (1) · Vesico-Ureteral Reflux (1)
Female Urogenital Diseases (11) · Female Urogenital Diseases and Pregnancy Complications (11) · Kidney Diseases (11) · Male Urogenital Diseases (11) · Nephritis (11) · Nephritis, Interstitial (11) · Pyelitis (11) · Urogenital Diseases (11) · Urologic Diseases (10) · Infections (7) · Bacterial Infections and Mycoses (3) · Urinary Bladder Diseases (3) · Enterobacteriaceae Infections (1) · Gram-Negative Bacterial Infections (1) · Nervous System Diseases (1)
Levofloxacin (3) · Doripenem (2) · Amoxicillin-Potassium Clavulanate Combination (1) · Cefepime (1) · Ceftibuten (1) · Ceftriaxone (1) · Edetic Acid (1) · Fosfomycin (1) · Meropenem (1) · Sulbactam (1) · Tazobactam (1) · Trimethoprim, Sulfamethoxazole Drug Combination (1) · bacitracin zinc, neomycin sulfate, polymyxin B, drug combination (1) · ceftolozane (1)
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (4) · Assistance Publique - Hôpitaux de Paris (1) · Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (1) · IRCCS Burlo Garofolo (1) · Janssen Research & Development, LLC (1) · Merck Sharp & Dohme LLC (1) · University of Alberta (1) · Venus Remedies Limited (1)
Brazil (2) · Colombia (2) · Latvia (2) · Mexico (2) · United States (2) · Argentina (1) · Canada (1) · Chile (1) · Czechia (1) · Estonia (1) · Georgia (1) · Germany (1) · Hungary (1) · India (1) · Israel (1)
A.K. Deb (1) · Darcie Kiddoo, MD (1) · Deepak Dewan (1) · Dharamraj Maurya (1) · Kim Mammen (1) · Madhav Prabhu (1) · Manjunath M (1) · Marzia Lazzerini, MD DTMH (1) · Mohd. Shameem (1) · Obiamiwe Umeh, M.D., MSc. (1) · Parvaiz Koul (1) · Pratibha Phadke (1)
PMID 19670912, PMID 20211892, PMID 21303745, PMID 17880755, PMID 18042477, PMID 18242357, PMID 25931244, PMID 26994090, PMID 27887579, PMID 27999024, PMID 28076247, PMID 28446129, PMID 28464828, PMID 31433059
2009 (1)